Assert-IQ vs Viz RV/LV
AI Verdict
Choose Assert-IQ if…
Choose Assert-IQ if you require long-term, continuous cardiac monitoring to diagnose and manage patients with suspected, infrequent, or asymptomatic heart rhythm disorders. Its ability to monitor for up to six years, coupled with advanced arrhythmia detection and remote alerts, makes it ideal for comprehensive, ongoing patient surveillance.
View Assert-IQ →Choose Viz RV/LV if…
Choose Viz RV/LV if your priority is rapid and automated risk stratification for suspected pulmonary embolism directly from CTPA scans. This AI algorithm quickly provides crucial RV/LV ratio measurements and integrates with care coordination tools, enabling swift clinical decision-making and team communication in acute settings.
View Viz RV/LV →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz RV/LVViz RV/LV (Tool B) offers a highly integrated and mobile-first experience for clinicians, including AI-powered alerts, a high-fidelity mobile DICOM image viewer, and a HIPAA-compliant communication platform for rapid care coordination [JSON, cite: 27]. This contrasts with Assert-IQ's (Tool A) patient-facing app for symptom logging and clinician access via a portal, making Tool B more dynamic for acute care workflows [JSON, cite: 2, 11, 26].
Clinical Value
Viz RV/LVWhile Assert-IQ (Tool A) provides significant value in long-term, continuous arrhythmia monitoring and diagnosis, Viz RV/LV (Tool B) offers rapid, automated risk stratification for acute, life-threatening pulmonary embolism [JSON]. Its ability to quickly measure RV/LV ratios and integrate with care coordination directly impacts immediate treatment decisions and has been shown to accelerate diagnostic and triage workflows.
Pricing & Value
Viz RV/LVBoth tools have opaque enterprise pricing that requires direct vendor contact, and neither offers a free trial [JSON]. However, Viz.ai, the company behind Viz RV/LV (Tool B), was ranked #1 in 'Return on Technology Investment' in a 2025 Black Book survey, indicating a strong perceived value proposition by its users.
Enterprise Readiness
Viz RV/LVBoth tools are FDA-cleared and HIPAA compliant, indicating readiness for large healthcare systems [JSON]. While Abbott (Tool A) is a well-established medical device company, Viz.ai (Tool B) has received specific accolades in a Black Book survey for 'Ease of Implementation & Adoption' and 'Compatibility in Multi-Vendor Environments' across over 1,200 health systems, demonstrating robust integration capabilities.
Innovation
Viz RV/LVAssert-IQ (Tool A) demonstrates innovation in long-term implantable cardiac monitoring with advanced AI algorithms and remote programmability [JSON, cite: 5, 8, 24]. However, Viz RV/LV (Tool B) leverages deep learning AI for rapid, automated image analysis and integrates it into a real-time, mobile-first care coordination platform for acute conditions, representing a more disruptive innovation in acute disease management workflows. Viz.ai was also ranked #1 in 'Innovation & Futureproofing' in a Black Book survey [JSON, cite: 7, 9, 12, 14, 27].
Support & Docs
Viz RV/LVAssert-IQ (Tool A) explicitly lists various clinician and patient manuals, along with remote monitoring support services. While Viz RV/LV (Tool B) does not detail its documentation in the provided facts, its parent company, Viz.ai, was ranked #1 in 'Vendor Responsiveness & Technical Support' in a 2025 Black Book survey, indicating strong user satisfaction with its support infrastructure.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | Viz RV/LV |
|---|---|---|
| Name | Assert-IQ | Viz RV/LV |
| Company | Abbott Medical | Viz.ai |
| Primary Function | Long-term, continuous cardiac monitoring and advanced arrhythmia detection. | Automated right and left ventricular diameter measurements from CTPA scans for pulmonary embolism risk stratification. |
| Key Feature Example | Long-term continuous cardiac monitoring (up to 6 years) | Automated Right Ventricle (RV) to Left Ventricle (LV) ratio measurement |
| Target Specialties | Cardiology, Internal Medicine | Emergency Medicine, Pulmonology, Radiology |
| Mobile App/Viewer | None | High-fidelity mobile DICOM image viewer |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and Viz RV/LV.